|Aegis Capital||Nathan Weinstein, CFA|
|Cantor Fitzgerald||Kristen Kluska|
|Oppenheimer||Jeff Jones, PhD|
Chemomab Therapeutics Ltd. (Chemomab) is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Chemomab performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Chemomab or its management. Chemomab does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.